FDA Approves First Chemotherapy-Free Treatment for Waldenström's Macroglobulinemia
August 27th 2018The FDA has approved ibrutinib (IMBRUVICA) plus rituximab (RITUXAN) for the treatment of adult patients with Waldenström's macroglobulinemia, a rare and incurable type of non-Hodgkin's lymphoma.
Read More
FDA OKs Treatment for 2 Rare Types of non-Hodgkin Lymphoma
August 8th 2018The FDA has approved mogamulizumab-kpkc (Poteligeo) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least 1 prior systemic therapy.
Read More
FDA Approves First Treatment for Rare Tumors of the Adrenal Gland
July 31st 2018The FDA has approved iobenguane I 131 (Azedra) injection for intravenous use for the treatment of adults and adolescents 12 years of age and older with rare adrenal gland tumors such as pheochromocytoma or paraganglioma that cannot be surgically removed, have spread beyond the original tumor site, and require systemic anticancer therapy.
Read More